Ana A Baumann1, Vincent Mutabazi2, Angela L Brown3, Cole Hooley1, Dominic Reeds4, Cecile Ingabire5, Vedaste Ndahindwa5, Aurore Nishimwe6, W Todd Cade7, Lisa de Las Fuentes8, Enola K Proctor1, Stephen Karengera9, Kenneth B Schecthman10, Charles W Goss10, Kevin Yarasheski11, Brad Newsome12, Eugene Mutimura2, Victor G Davila-Roman13. 1. Brown School of Social Work, Washington University in St. Louis, St. Louis, MO, USA. 2. Regional Alliance for Sustainable Development, Kigali, Rwanda. 3. Cardiovascular Imaging and Clinical Research Core Laboratory, Cardiovascular Division, Washington University School of Medicine, St. Louis, MO, USA. 4. Division of Geriatrics and Nutritional Science, Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO, USA. 5. School of Nursing and Midwifery, University of Rwanda, Kigali, Rwanda. 6. School of Health Sciences, University of Rwanda, Kigali, Rwanda. 7. Program in Physical Therapy, Washington University School of Medicine, St. Louis, MO, USA. 8. Cardiovascular Imaging and Clinical Research Core Laboratory, Cardiovascular Division, Washington University School of Medicine, St. Louis, MO, USA; Divisions of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA. 9. Regional Alliance for Sustainable Development, Kigali, Rwanda; EAC RCE-VIHSCM, College of Medicine and Heath Sciences, University of Rwanda, Kigali, Rwanda. 10. Divisions of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA. 11. C2N Diagnostics, LLC, St. Louis, MO, USA. 12. National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. 13. Cardiovascular Imaging and Clinical Research Core Laboratory, Cardiovascular Division, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: vdavila@wustl.edu.
Abstract
BACKGROUND: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide and in low- and middle-income countries, and hypertension (HTN) is a major risk factor for CVD. Although effective evidence-based interventions for control of HTN in high-income countries exist, implementation of these in low- and middle-income countries has been challenging due to limited capacity and infrastructure for late-phase translational research. In Rwanda, the 2015 STEPS NCD (STEPwise Approach to Surveillance of Noncommunicable Diseases) risk survey reported an overall prevalence of HTN of 15% (95% confidence interval [CI]: 13.8 to 16.3) for those ages 15 to 64 years; prevalence increased with increasing age to 39% (95% CI: 35.7 to 43.1) for those ages 55 to 64 years; CVD was the third most common cause of mortality (7%). Suboptimal infrastructure and capacity in Rwanda hinders research and community knowledge for HTN control. OBJECTIVES: To address the issue of suboptimal capacity to implement evidence-based interventions in HTN, this project was designed with the following objectives: 1) to develop a regional needs assessment of infrastructure for dissemination and implementation (D & I) strategies for HTN-CVD control; 2) to develop HTN-CVD research capacity through creation of countrywide resources such as core research facilities and training in the fields of HTN-CVD, D & I, and biostatistics; and 3) to engage and train multiple stakeholders in D & I and HTN-CVD evidence-based interventions. METHODS: A weeklong training program in HTN-CVD, biostatistics, and D & I was conducted in Rwanda in August 2018, and pre- and post-D & I training competency questionnaires were administered. RESULTS: Questionnaire results show a statistically significant increase in D & I knowledge and skills as a result of training (full scale pre- to post-test scores: 2.12 ± 0.78 vs. 3.94 ± 0.42; p < 0.0001). CONCLUSIONS: Using principles of community engagement and train-the-trainer methods, we will continue to adapt guidelines and treatments for HTN-CVD developed in high-income countries to the context of Rwanda with the goal of establishing a sustainable platform to address the burden of disease from HTN-CVD.
BACKGROUND:Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide and in low- and middle-income countries, and hypertension (HTN) is a major risk factor for CVD. Although effective evidence-based interventions for control of HTN in high-income countries exist, implementation of these in low- and middle-income countries has been challenging due to limited capacity and infrastructure for late-phase translational research. In Rwanda, the 2015 STEPS NCD (STEPwise Approach to Surveillance of Noncommunicable Diseases) risk survey reported an overall prevalence of HTN of 15% (95% confidence interval [CI]: 13.8 to 16.3) for those ages 15 to 64 years; prevalence increased with increasing age to 39% (95% CI: 35.7 to 43.1) for those ages 55 to 64 years; CVD was the third most common cause of mortality (7%). Suboptimal infrastructure and capacity in Rwanda hinders research and community knowledge for HTN control. OBJECTIVES: To address the issue of suboptimal capacity to implement evidence-based interventions in HTN, this project was designed with the following objectives: 1) to develop a regional needs assessment of infrastructure for dissemination and implementation (D & I) strategies for HTN-CVD control; 2) to develop HTN-CVD research capacity through creation of countrywide resources such as core research facilities and training in the fields of HTN-CVD, D & I, and biostatistics; and 3) to engage and train multiple stakeholders in D & I and HTN-CVD evidence-based interventions. METHODS: A weeklong training program in HTN-CVD, biostatistics, and D & I was conducted in Rwanda in August 2018, and pre- and post-D & I training competency questionnaires were administered. RESULTS: Questionnaire results show a statistically significant increase in D & I knowledge and skills as a result of training (full scale pre- to post-test scores: 2.12 ± 0.78 vs. 3.94 ± 0.42; p < 0.0001). CONCLUSIONS: Using principles of community engagement and train-the-trainer methods, we will continue to adapt guidelines and treatments for HTN-CVD developed in high-income countries to the context of Rwanda with the goal of establishing a sustainable platform to address the burden of disease from HTN-CVD.
Authors: Gregory A Roth; Grant Nguyen; Mohammad H Forouzanfar; Ali H Mokdad; Mohsen Naghavi; Christopher J L Murray Journal: Circulation Date: 2015-09-29 Impact factor: 29.690
Authors: George A Mensah; Zorina S Galis; Lawrence J Fine; Melissa E Garcia; Daniel F Levy; Gary H Gibbons Journal: Hypertension Date: 2016-11-14 Impact factor: 10.190
Authors: Conall M O'Seaghdha; Vlado Perkovic; Tai Hing Lam; Stella McGinn; Federica Barzi; Dong Feng Gu; Alan Cass; Il Suh; Paul Muntner; Graham G Giles; Hirotsugu Ueshima; Mark Woodward; Rachel Huxley Journal: Hypertension Date: 2009-07-13 Impact factor: 10.190
Authors: M J Klag; P K Whelton; B L Randall; J D Neaton; F L Brancati; C E Ford; N B Shulman; J Stamler Journal: N Engl J Med Date: 1996-01-04 Impact factor: 91.245
Authors: Michel Joffres; Emanuela Falaschetti; Cathleen Gillespie; Cynthia Robitaille; Fleetwood Loustalot; Neil Poulter; Finlay A McAlister; Helen Johansen; Oliver Baclic; Norm Campbell Journal: BMJ Open Date: 2013-08-30 Impact factor: 2.692
Authors: Thomas J Waltz; Byron J Powell; Monica M Matthieu; Laura J Damschroder; Matthew J Chinman; Jeffrey L Smith; Enola K Proctor; JoAnn E Kirchner Journal: Implement Sci Date: 2015-08-07 Impact factor: 7.327
Authors: David A Cook; Laurie J Pencille; Denise M Dupras; Jane A Linderbaum; V Shane Pankratz; John M Wilkinson Journal: PLoS One Date: 2018-01-31 Impact factor: 3.240
Authors: Evariste Ntaganda; Regine Mugeni; Emmanuel Harerimana; Gedeon Ngoga; Symaque Dusabeyezu; Francois Uwinkindi; Jean N Utumatwishima; Eugene Mutimura; Victor G Davila-Roman; Kenneth Schechtman; Aurore Nishimwe; Laurence Twizeyimana; Angela L Brown; W Todd Cade; Marcus Bushaku; Lisa de Las Fuentes; Dominic Reeds; Marc Twagirumukiza Journal: BMC Cardiovasc Disord Date: 2022-04-26 Impact factor: 2.174
Authors: Ashlin Rakhra; Cole Hooley; Meredith Fort; Mary Beth Weber; LeShawndra Price; Hoa L Nguyen; Manuel Ramirez; Adamson S Muula; Mina Hosseinipour; Kingsley Apusiga; Victor Davila-Roman; Joyce Gyamfi; Kezia Gladys Amaning Adjei; Josephine Andesia; Annette Fitzpatrick; Pascal Launois; Ana A Baumann Journal: Res Sq Date: 2022-03-29
Authors: Cole Hooley; Ana A Baumann; Vincent Mutabazi; Angela Brown; Dominic Reeds; W Todd Cade; Lisa de Las Fuentes; Enola K Proctor; Stephen Karengera; Kenneth Schecthman; Charles Goss; Pascal Launois; Victor G Davila-Roman; Eugene Mutimura Journal: Pilot Feasibility Stud Date: 2020-05-15